In an editorial, researchers Gregory L. Guzik and Ankit Mangla from University Hospitals Cleveland Medical Center, University Hospitals Seidman Cancer Center, Case Western Reserve University School of Medicine, and Case Comprehensive ...
Jun 21, 2024
0
0
Hepatocellular carcinoma (HCC) presents significant challenges due to its high incidence and mortality rates, particularly in China where most patients are diagnosed at intermediate or advanced stages. This limits the applicability ...
Jun 21, 2024
0
0
Robin Zenlander from the Gastroenterology and Rheumatology Unit at the Department of Medicine, Huddinge, is defending his thesis titled "Biomarkers in hepatocellular carcinoma," on 13 June, 2024.
Jun 12, 2024
0
0
A new, healthy liver offers the best survival for patients with early-stage liver cancer. But a new study, led by Katie Ross-Driscoll, Ph.D., MPH, of Regenstrief Institute and Indiana University School of Medicine Department ...
Jun 10, 2024
0
0
In contrast to traditional cancer treatments such as surgery, chemotherapy, and radiotherapy, photodynamic therapy (PDT) is emerging as a novel method that uses specific wavelengths of light to activate photosensitizers. ...
May 28, 2024
0
0
Hepatocellular carcinoma (HCC) represents a significant global health burden as one of the most common malignancies in individuals with chronic liver disease or cirrhosis. This malignancy evolves through a multistep process, ...
May 24, 2024
0
0
Hepatocellular carcinoma (HCC), a prevalent form of cancer, profoundly influences the progression and prognosis of the disease through immune response mechanisms. The tumor microenvironment plays a pivotal role in fostering ...
May 22, 2024
0
0
Liver transplantation is a life-saving option for those with hepatocellular carcinoma (HCC), the most prevalent type of liver cancer. Although often successful, outcomes can vary widely among recipients.
May 9, 2024
0
0
In a study published in Science on May 3, researchers unveiled two responding patterns of tumor-infiltrating B cells with therapeutic implications.
May 6, 2024
0
29
A drug that targets a protein known as phosphatidylserine boosted the response rate for hepatocellular carcinoma (HCC) patients receiving immunotherapy without compromising their safety, according to results of a phase two ...
May 3, 2024
0
52
Hepatocellular carcinoma (HCC, also called malignant hepatoma) is the most common type of liver cancer. Most cases of HCC are secondary to either a viral hepatitide infection (hepatitis B or C) or cirrhosis (alcoholism being the most common cause of hepatic cirrhosis).
Compared to other cancers, HCC is quite a rare tumor in the United States. In countries where hepatitis is not endemic, most malignant cancers in the liver are not primary HCC but metastasis (spread) of cancer from elsewhere in the body, e.g., the colon. Treatment options of HCC and prognosis are dependent on many factors but especially on tumor size and staging. Tumor grade is also important. High-grade tumors will have a poor prognosis, while low-grade tumors may go unnoticed for many years, as is the case in many other organs, such as the breast, where a ductal carcinoma in situ (or a lobular carcinoma in situ) may be present without any clinical signs and without correlate on routine imaging tests, although in some occasions it may be detected on more specialized imaging studies like MR mammography.
This text uses material from Wikipedia licensed under CC BY-SA
